Routine follow-up visits after first-trimester induced abortion

Obstetrics and Gynecology

Volumn 103, Issue 4, 2004, Pages 738-745

  Grossman, Daniel ^a   Ellertson, Charlotte ^b   Grimes, David A ^b   Walker, Dilys ^b  

^a POPULATION COUNCIL   (Mexico)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; MIFEPRISTONE;

CONSULTATION; CONTRACEPTION; COST BENEFIT ANALYSIS; ECTOPIC PREGNANCY; FAMILY PLANNING; FIRST TRIMESTER PREGNANCY; FOLLOW UP; GESTATIONAL AGE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HUMAN; INDUCED ABORTION; PAPANICOLAOU TEST; PATIENT COUNSELING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REPRODUCTIVE HEALTH; REVIEW; SEXUALLY TRANSMITTED DISEASE; AFTERCARE; FEMALE; PREGNANCY;

ABORTION, INDUCED; AFTERCARE; FEMALE; FOLLOW-UP STUDIES; HUMANS; PREGNANCY; PREGNANCY TRIMESTER, FIRST;

EID: 2342644933     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000115511.14004.19     Document Type: Review

References (69)

1. Finer LB, Henshaw SK. Abortion incidence and services in the United States in 2000. Perspect Sex Reprod Health 2003;35:6-15.
2. Newhall EP, Winikoff B. Abortion with mifepristone and misoprostol: regimens, efficacy, acceptability and future directions. Am J Obstet Gynecol 2000;183(suppl):S44-53.
3. Keder LM. Best practices in surgical abortion. Am J Obstet Gynecol 2003;189:418-22.
4. Paul M. Office management of early induced abortion. Clin Obstet Gynecol 1999;42:290-305.
5. Policar MJ, Pollack AE. Clinical training curriculum in abortion practice. Washington, DC: National Abortion Federation; 1995. p. 116.
6. Darney PD, Horbach NS, Korn AP. First-trimester elective abortion. In: Protocols for office gynecologic surgery. Cambridge (MA): Blackwell Science; 1996. p. 158-93.
7. Planned Parenthood Federation of America, Inc. Manual of medical standards and guidelines. New York (NY): Planned Parenthood Federation of America; 2002. Section VII-A-1, p. 13.
8. Royal College of Obstetricians and Gynaecologists Clinical Effectiveness Support Unit. The care of women requesting induced abortion. March 2000. Available at: http://www.nelh.nhs.uk/guidelinesdb/html/front/InducedAbortion. html. Retrieved April 10, 2003.
9. Flett GM, Templeton A. Surgical abortion. Best Pract Res Clin Obstet Gynaecol 2002;16:247-61.
10. McIntosh KM, Stewart GK, Teplin D. Routine aftercare and contraception. In: Paul M, Lichtenberg ES, Borgatta L, Grimes DA, Stubblefield PG, editors. A clinician's guide to medical and surgical abortion. Philadelphia (PA): Churchill Livingstone; 1999. p. 185-96.
11. Marie Slopes International. Clinical standards training manual. London: Marie Slopes International; 2002. p. 24.
12. Jones RK, Henshaw SK. Mifepristone for early medical abortion: experiences in France, Great Britain and Sweden. Perspect Sex Reprod Health 2002;34:154-61.
13. Planned Parenthood Federation of America, Inc. Manual of medical standards and guidelines. New York (NY): Planned Parenthood Federation of America; 2002. Section VII-B-1, p. 1-20.
14. Westfall JM, Sophocles A, Burggraf H, Ellis S. Manual vacuum aspiration for first-trimester abortion. Arch Fam Med 1998;7:559-62.
15. Paul M, Lackie E, Mitchell C, Rogers A, Fox M. Is pathology examination useful after early surgical abortion? Obstet Gynecol 2002;99:567-71.
16. Fielding WL, Lee SY, Borten M, Friedman EA. Continued pregnancy after failed first-trimester abortion. Obstet Gynecol 1984;63:421-4.
17. Cameron ST, Glasier AF, Logan J, Benton L, Baird DT. Impact of the introduction of new medical methods on therapeutic abortions at the Royal Infirmary of Edinburgh. Br J Obstet Gynaecol 1996;103:1222-9.
18. Hakim-Elahi E, Tovell HM, Burnhill MS. Complications of first-trimester abortion: a report of 170,000 cases. Obstet Gynecol 1990;76:129-35.
19. Thonneau P, Fougeyrollas B, Ducot B, Boubilley D, Dif J, Lalande M, et al. Complications of abortion performed under local anesthesia. Eur J Obstet Gynecol Reprod Biol 1998;81:59-63.
20. Freedman MA, Jillson DA, Coffin RR, Novick LF. Comparison of complication rates in first trimester abortions performed by physician assistants and physicians. Am J Public Health 1986;76:550-4.
21. Ntaganira I, Germain M, Guilbert E. Les facteurs associes au non-retour a la visite de suivi précoce post-avortement [Factors associated with follow-up visit non-compliance after induced abortion]. Can J Public Health 1998;89:62-5.
22. Kaunitz AM, Rovira EZ, Grimes DA, Schulz KF. Abortions that fail. Obstet Gynecol 1985;66:533-7.
23. Lichtenberg ES, Grimes DA, Paul M. Abortion complications: prevention and management. In: Paul M, Lichtenberg ES, Borgatta L, Grimes DA, Stubblefield PG, editors. A clinician's guide to medical and surgical abortion. Philadelphia (PA): Churchill Livingstone; 1999. p. 197-216.
24. Child TJ, Thomas J, Rees M, MacKenzie IZ. Morbidity of first trimester aspiration termination and the seniority of the surgeon. Hum Reprod 2001;16:875-8.
25. Edwards J, Carson SA. New technologies permit safe abortion at less than six weeks' gestation and provide timely detection of ectopic gestation. Am J Obstet Gynecol 1997;176:1101-6.
26. Edwards J, Creinin MD. Surgical abortion for gestations of less than 6 weeks. Curr Probl Obstet Gynecol Fertil 1997; 20:11-9.
27. Spitz IM, Bardin CW, Benton L, Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. N Engl J Med 1998;338:1241-7.
28. Creinin MD, Vittinghoff E, Keder L, Darney PD, Tiller G. Methotrexate and misoprostol for early abortion: a multicenter trial. I. Safety and efficacy. Contraception 1996;53: 321-7.
29. Wheeler M, O'Meara P, Stanford M. Fetal methotrexate and misoprostol exposure: the past revisited. Teratology 2002;66:73-6.
30. Gonzalez CH, Marques-Dias MJ, Kim CA, Sugayama SM, Da Paz JA, Huson SM, et al. Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy. Lancet 1998;351:1624-7.
31. Vargas FR, Schuler-Faccini L, Brunoni D, Kim C, Meloni VF, Sugayama SM, et al. Prenatal exposure to misoprostol and vascular disruption defects: a case-control study. Am J Med Genet 2000;95:302-6.
32. Coelho KE, Sarmento MF, Veiga CM, Speck-Martins CE, Safatle HP, Castro CV, et al. Misoprostol embryotoxicity: clinical evaluation of fifteen patients with arthrogryposis. Am J Med Genet 2000;95:297-301.
33. Pastuszak AL, Schuler L, Speck-Martins CE, Coelho KE, Cordello SM, Vargas F, et al. Use of misoprostol during pregnancy and Mobius' syndrome in infants. N Engl J Med 1998;338:1881-5.
34. Orioli IM, Castilla EE. Epidemiological assessment of misoprostol teratogenicity. BJOG 2000;107:519-23.
35. Schuler L, Pastuszak A, Sanseverino TV, Orioli IM, Brunoni D, Ashton-Prolla P, et al. Pregnancy outcome after exposure to misoprostol in Brazil: a prospective, controlled study. Reprod Toxicol 1999;13:147-51.
36. Ellertson E, Elul B, Winikoff B. Can women use medical abortion without medical supervision? Reprod Health Matters 1997;9:149-61.
37. Harper C, Ellertson C, Winikoff B. Could American women use mifepristone-misoprostol pills safely with less medical supervision? Contraception 2002;65:133-42.
38. Kaali SG, Csakany GM, Szigetvari I, Barad DH. Updated screening protocol for abortion services. Obstet Gynecol 1990;76:136-8.
39. Centers for Disease Control and Prevention. Ectopic Pregnancy - United States, 1990-1992. MMWR Morb Mortal Wkly Rep 1995;44:46-8.
40. Rubin GL, Cates W Jr, Gold J, Rochat RW, Tyler CW Jr. Fatal ectopic pregnancy after attempted legally induced abortion. JAMA 1980;244:1705-8.
41. Peterson WF, Berry FN, Grace MR, Gulbranson CL. Second-trimester abortion by dilatation and evacuation: an analysis of 11,747 cases. Obstet Gynecol 1983;62:185-90.
42. Paul M, Schaff E, Nichols M. The roles of clinical assessment, human chorionic gonadotropin assays, and ultrasonography in medical abortion practice. Am J Obstet Gynecol. 2000;183:S34-43.
43. Borgatta L, Burnhill M, Haskell S, Nichols M, Leonhardt K. Instituting medical abortion services: changes in outcome and acceptability related to provider experience. J Am Med Womens Assoc 2000;55:173-6.
44. Suhonen S, Heikinheimo O, Tikka M, Haukkamaa M. The learning curve is rapid in medical termination of pregnancy: first-year results from the Helsinki area. Contraception 2003;67:223-7.
45. Kruse B, Poppema S, Creinin MD, Paul M. Management of side effects and complications in medical abortion. Am J Obstet Gynecol 2000;183(suppl):S65-75.
46. Lähteenmäki P. Postabortal contraception. Ann Med 1993;25:185-9.
47. Marrs RP, Kletzky OA, Howard WF, Mishell DR Jr. Disappearance of human chorionic gonadotropin and resumption of ovulation following abortion. Am J Obstet Gynecol 1979;135:731-6.
48. Peterson WF. Contraceptive therapy following therapeutic abortion: an analysis. Obstet Gynecol 1974;44:853-7.
49. Kurunmäki H. Contraception with levonorgestrel-releasing subdermal capsules, Norplant, after pregnancy termination. Contraception 1983;27:473-82.
50. Ortayli N, Bulut A, Sahin T, Sivin I. Immediate postabortal contraception with the levonorgestrel intrauterine device, Norplant, and traditional methods. Contraception 2001;63:309-14.
51. WHO Task Force on IUDs for Fertility Regulation. IUD insertion following termination of pregnancy: a clinical trial of the Tcu 220C, Lippes loop D, and copper 7. Stud Fam Plann 1983;14:99-108.
52. Lim LS, McCarthy TG, Yong YM, Ratnam SS. Postabortion insertion of MLCu 250 and MLCu 375: a comparative trial. Contraception 1985;31:471-7.
53. Pakarinen P, Toivonen J, Luukkainen T. Randomized comparison of levonorgestrel- and copper-releasing intra-uterine systems immediately after abortion, with 5 years' follow-up. Contraception 2003;68:31-4.
54. Stanwood NL, Grimes DA, Schulz KF. Insertion of an intrauterine contraceptive device after induced or spontaneous abortion: a review of the evidence. BJOG 2001;108: 1168-73.
55. Goldberg AB, Cardenas LH, Hubbard AE, Barney PD. Post-abortion depot medroxyprogesterone acetate continuation rates: a randomized trial of cyclic estradiol (E2). Contraception 2002;66:215-20.
56. Polaneczky M, Guarnaccia M, Alon J, Wiley J. Early experience with the contraceptive use of depot medroxyprogesterone acetate in an inner-city clinic population. Fam Plann Perspect 1996;28:174-8.
57. Lim SW, Rieder J, Coupey SM, Bijur PE. Depot medroxyprogesterone acetate use in inner-city, minority adolescents: continuation rates and characteristics of long-term users. Arch Pediatr Adolesc Med 1999;153:1068-72.
58. Adler NE, David HP, Major BN, Roth SH, Russo NF, Wyatt GE. Psychological factors in abortion: a review. Am Psychol 1992;47:1194-204.
59. Dagg PKB. The psychological sequelae of therapeutic abortion: denied and completed. Am J Psychiatry 1991; 148:578-85.
60. Stotland NL. Psychosocial aspects of induced abortion. Clin Obstet Gynecol 1997;40:673-86.
61. Stotland NL. Psychiatric issues related to infertility, reproductive technologies, and abortion. Prim Care 2002;29: 13-26.
62. The Alan Guttmacher Institute. State facts about abortion: national background. Available at: http://www.guttmacher. org/pubs/sfaa/california.html. Retrieved August 6, 2003.
63. Henshaw SK, Finer LB. The accessibility of abortion services in the United States, 2001. Perspect Sex Reprod Health 2003;35:16-24.
64. Click E. First trimester abortion. In: Surgical abortion. Reno (NV): West End Women's Medical Group; 1998. p. 2-43.
65. Elam-Evans LD, Strauss LT, Herndon J, Parker WY, Whitehead S, Berg CJ. Abortion surveillance: United States, 1999. MMWR Surveill Summ 2002;51:1-9, 11-28.
66. Fallis WM, Scurrah D. Outpatient laparoscopic cholecystectomy: home visit versus telephone follow-up. Can J Surg 2001;44:39-44.
67. Puri R, Smaling A, Lloyd SN. How is follow-up after transurethral prostatectomy best performed? BJU Int 1999; 84:795-8.
68. Khan Y, Fitzgerald P, Walton M. Assessment of the postoperative visit after routine inguinal hernia repair: a prospective randomized trial. J Pediatr Surg 1997;32:892-3.
69. Schaff EA, Eisinger SH, Stadalius LS, Franks P, Gore BZ, Poppema S. Low-dose mifepristone 200 mg and vaginal misoprostol for abortion. Contraception 1999;59:1-6.